PMID- 32492939
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 1
TI  - Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A 
      Narrative Review.
LID - 10.3390/jcm9061677 [doi]
LID - 1677
AB  - The 2017 World Health Organization (WHO) classification of neuroendocrine 
      neoplasms (NEN) of the digestive tract introduced a new category of tumors named 
      well-differentiated grade 3 neuroendocrine tumors (NET G-3). These lesions show a 
      number of mitosis, or a Ki-67 index higher than 20% with a well-differentiated 
      morphology, therefore separating them from neuroendocrine carcinomas (NEC) which 
      are poorly differentiated. It has become clear that NET G-3 show differences not 
      only in morphology but also in genotype, clinical presentation, and treatment 
      response. The incidence of digestive NET G-3 represents about one third of NEN 
      G-3 with main tumor sites being the pancreas, the stomach and the colon. 
      Treatment for NET G-3 is not yet standardized because of lack of data. In a 
      non-metastatic setting, international guidelines recommend surgical resection, 
      regardless of tumor grading. For metastatic lesion, chemotherapy is the main 
      treatment with similar regimen as NET G-2. Sunitinib has also shown some positive 
      results in a small sample of patients but this needs confirmation. Peptide 
      receptor radionuclide therapy (PRRT) and immunotherapy could be future available 
      treatments after ongoing studies. The goal of this review was to sum up the 
      latest data on the epidemiology and management of digestive NET G-3.
FAU - Pellat, Anna
AU  - Pellat A
AD  - Department of Gastroenterology and digestive oncology, Cochin Teaching Hospital, 
      AP-HP, 75014 Paris, France.
AD  - Faculte de Medecine, Universite de Paris, 75006 Paris, France.
AD  - Oncology Unit, Hopital Saint Antoine, AP-HP, Sorbonne Universite, 75012 Paris, 
      France.
FAU - Coriat, Romain
AU  - Coriat R
AUID- ORCID: 0000-0003-4420-8340
AD  - Department of Gastroenterology and digestive oncology, Cochin Teaching Hospital, 
      AP-HP, 75014 Paris, France.
AD  - Faculte de Medecine, Universite de Paris, 75006 Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200601
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7357105
OTO - NOTNLM
OT  - grade 3
OT  - neuroendocrine tumor
OT  - well-differentiated
COIS- The authors declare no conflict of interest.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
PMCR- 2020/06/01
CRDT- 2020/06/05 06:00
PHST- 2020/04/18 00:00 [received]
PHST- 2020/05/27 00:00 [revised]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - jcm9061677 [pii]
AID - jcm-09-01677 [pii]
AID - 10.3390/jcm9061677 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jun 1;9(6):1677. doi: 10.3390/jcm9061677.